About us

The International Generic Drug Regulators Programme (IGDRP) was created in 2011 to promote collaboration and convergence of generic drug regulators in order to address challenges posed by increasing workloads, globalization and complexity of scientific issues.

Initially formed as a three year International Generic Drug Regulators Pilot ('IGDR Pilot'), at its seventh meeting in Singapore in November 2014 the achievements of the IGDRP led to its establishment as a permanent programme for international collaboration in the assessment of generic drugs.

Terms of Reference

IGDRP Terms of Reference (updated 9 June 2017)

IGDRP Roadmap to 2020

The availability of quality generic medicines plays an increasingly important role in helping to address rising health care costs and in promoting access to essential medicines worldwide. This, however, has led to significant pressures on regulatory authorities (RAs) tasked with the review and authorisation of these drug products. Among other objectives, the IGDRP initiative has the ambition to increase the efficiency of review procedures and reduce regulatory burden without comprising the safety, efficacy, and quality of generic medicines. Given these challenges, the benefits of regulatory cooperation, convergence and harmonisation have long been recognised.

The IGDRP Roadmap to 2020 describes these shared goals and objectives and makes available a strategic vision to articulate and guide the collective efforts of IGDRP in terms of where we are going and how we are going to get there. The document describes five overarching strategic priorities for the initiative as well the key objectives for each of these priorities. The IGDRP will develop and maintain strong, formal communication channels with other international initiatives and is currently developing performance measurement tools to assess the impact and success of the programme against its intended objectives.

IGDRP Membership Form

The completed membership form must be provided to the IGDRP Secretariat by any Regulatory Authority (RA) or a Group of RAs wishing to either:

  • become an IGDRP Member- at least 60 days before the next face to face meeting;
  • become an Observer- at least 60 days before the next face to face meeting; or
  • attend a Steering Committee or Working Group meeting on an ad-hoc basis as a temporary Guest- at least 30 days before the meeting.

The IGDRP Steering Committee will consider all requests for Membership or Observers at the face to face meeting following receipt of a completed membership form. If endorsed, an RA or a Group of RAs will gain their Member of Observer status immediately following the face to face meeting.
An RA or a Group of RAs may attend the face-to-face meeting immediately following submission of a completed membership form, as a temporary Observer.
All fields on the membership form must be completed.

IGDRP Membership form

Participating agencies and organisations

Members

Observers